J. Fraser Wright - Concepedia

Author

J. Fraser Wright

Children's Hospital of Philadelphia ORCID

Also Known As

J F Wright, J Fraser Wright, J Fraser Wright, Ph.D, J Wright, J. F. WRIGHT, J. F. Wright, J. Fraser Wright, J. Wright, J.F. WRIGHT, J.F. Wright

120

Publications

17.2K

Citations

H-Index

Concepts

All Affiliations

Children's Hospital of Philadelphia University of Pennsylvania Howard Hughes Medical Institute Telethon Institute Of Genetics And Medicine Stanford University

About

J. Fraser Wright is an author at Children's Hospital of Philadelphia specializing in medicine, virology, and immunology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	21	22	10.6K
2	Natural Sciences	2	2	56
3	Engineering	1	1	152
4	Health Sciences	1	1	96
5	Public Health	1	1	41

J. Fraser Wright

Publications

15.8K

Citations

H-Index

Page 1

	Year	Citations
Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia Stephan A. Grupp, Michael Kalos, David M. Barrett, New England Journal of Medicine T-regulatory CellImmune RegulationImmunologyImmunodominanceCd4 T Cell Responses	2013	3.4K
Safety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis Albert M. Maguire, Francesca Simonelli, Eric A. Pierce, New England Journal of Medicine Ocular DiseaseGeneticsImmunologyPathologyDisease Gene Identification	2008	2.1K
Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65 -mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial Stephen R. Russell, Jean Bennett, Jennifer Wellman, The Lancet Ocular DiseaseRetinaOphthalmologyExperimental OphthalmologyVoretigene Neparvovec	2017	1.8K
Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial Albert M. Maguire, Katherine A. High, Alberto Auricchio, The Lancet Gene TherapiesGenetic DisorderGeneticsClinical TrialsTranslational Research	2009	849
Hemophilia B Gene Therapy with a High-Specific-Activity Factor IX Variant Lindsey A. George, Spencer K. Sullivan, Adam Giermasz, New England Journal of Medicine	2017	736
Gene Therapy for Leber's Congenital Amaurosis is Safe and Effective Through 1.5 Years After Vector Administration Francesca Simonelli, Albert M. Maguire, Francesco Testa, Molecular Therapy	2009	544
Safety and durability of effect of contralateral-eye administration of AAV2 gene therapy in patients with childhood-onset blindness caused by RPE65 mutations: a follow-on phase 1 trial Jean Bennett, Jennifer Wellman, Kathleen Marshall, The Lancet Translational MedicineGene TherapiesOcular DiseaseAav2 Gene TherapyIn Vivo Gene Therapy	2016	445
AAV2 Gene Therapy Readministration in Three Adults with Congenital Blindness Jean Bennett, Manzar Ashtari, Jennifer Wellman, Science Translational Medicine Gene TherapiesTranslational MedicineRpe65 GeneRetinaIn Vivo Gene Therapy	2012	387
Efficacy, Safety, and Durability of Voretigene Neparvovec-rzyl in RPE65 Mutation–Associated Inherited Retinal Dystrophy Albert M. Maguire, Stephen R. Russell, Jennifer Wellman, Ophthalmology	2019	362
Overcoming Preexisting Humoral Immunity to AAV Using Capsid Decoys Federico Mingozzi, Xavier M. Anguela, Giulia Pavani, Science Translational Medicine	2013	335

Page 1